“Primovist not only offers the unique benefit of being able to simultaneously detect, locate and distinguish various types of liver lesions, but also helps to guide and follow-up on treatment decisions, as it enables radiologists to identify even tiny pathological liver lesions,” said Dr. Gunnar Riemann, Member of the Board of Management of Bayer Schering Pharma AG, responsible for the company’s Business Units. “Bayer is now in the unique position of offering Primovist for diagnosing patients with liver cancer and Nexavar for treating hepatocellular carcinoma – the most common form of liver cancer.”
More info here
Doreen SchröderTelefon: +49 30 468-11399Fax: +49 30 468-16710 (berlin)
|Sponsor:||Fred Hutchinson Cancer Research Center|
|Collaborators:||Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma|
University of Washington
|Information provided by:||Fred Hutchinson Cancer Research Center|
The purpose of this study is to determine if a new magnetic resonance (MR) protocol is better at diagnosing liver lesions.
|Study Design:||Observational Model: Cohort|
Time Perspective: Prospective
|Official Title:||Dynamic Contrast Evaluation of the Liver Using Gadoxetate Disodium (Eovist®) for Hepatocellular Carcinoma (HCC)|
- Accuracy of a new MR protocol in diagnosing HCC and other liver lesions. [ Time Frame: One day: participants will have one MRI of the liver. ] [ Designated as safety issue: No ]
|Study Start Date:||August 2010|
|Estimated Study Completion Date:||December 2013|
|Estimated Primary Completion Date:||December 2013 (Final data collection date for primary outcome measure)|
Hepatocellular carcinoma (HCC), a form of liver cancer, is the seventh most common cause of cancer mortality in the US. The incidence rate of HCC is increasing along with the incidence of Hepatitis B and C which are known to promote HCC. Patients have a better prognosis (survival outlook) if HCC is found and treated at an early stage. MRI is the best imaging modality for diagnosing HCC.
This study will compare standard MRIs and MRIs performed with a newly developed MR protocol to determine if it is possible to more confidently diagnose HCC.
Contacts and Locations
|Principal Investigator:||Orpheus Kolokythas, MD||University of Washington|